A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group. by Anderson, H. et al.
Br. J. ofCancer (1984), 49, 695-702
A randomised study of adjuvant chemotherapy after mantle
radiotherapy in supradiaphragmatic Hodgkin's disease PS
IA-IIB: A report from the Manchester lymphoma group
H. Anderson', D.P. Deakin2, J. Wagstaff', J.M. Jones3, I.D.H. Todd2,
P.M. Wilkinson2, R.D. James2, W.P. Steward1, G. Blackledge4, J.H. Scarffe
& D. Crowther'
'Dept. Medical Oncology, 2Dept. Radiotherapy, and 3Dept. Medical Statistics, Christie Hospital, Manchester,
M20 9BX, 4Dept. Clinical Oncology, Queen Elizabeth Hospital, Birmingham 15, UK.
Summary One hundred and fourteen untreated patients with pathological stage (PS) IA-IIB
supradiaphragmatic Hodgkin's Disease were randomised to mantle radiotherapy alone (55) or mantle
radiotherapy followed by 6 courses of adjuvant chemotherapy with mustine, vinblastine, prednisolone and
procarbazine- MVPP (59). Patients excluded were those outside the age range 16-65 years and those with
massive mediastinal disease precluding laparotomy. Bulk disease was defined as a mass of lymph nodes
measuring five centimetres or more in any axis. Mediastinal bulk was present if the ratio of the maximum
width of mediastinal disease to the maximal chest diameter was more than one third..
All patients achieved a complete remission. Median duration of follow-up was 62 months (range 16-97).
The relapse free survival (RFS) was 81%; 69% for radiotherapy alone and 93% for adjuvant chemotherapy
(P=0.002). RFS was also shown to be adversely affected by B symptoms (P=0.0003), bulk disease
(P=0.018), abnormal CXR (P=0.037), and increasing stage (P=0.039). Age, sex, histology, and number of
sites involved had no significant effect upon RFS. A Cox multivariate analysis showed that only three
variables had a significant adverse effect on RFS - radiotherapy alone, the presence of bulk disease, and B
symptoms. The overall 5 year survival was 93% with no statistically significant difference between the two
treatment groups (P=0.54). Survival was adversely affected by three variables - B symptoms (P=0.02), the
presence of bulk disease (P=0.002), and pathological stage (P=0.05).
High risk groups for relapse are those with bulk and B symptoms. This analysis has shown that RFS was
significantly improved by adjuvant chemotherapy, but that overall survival was not.
In 1913 Finzi advocated irradiation of uninvolved
sites in patients with Hodgkin's disease in an
attempt to procure long term RFS (Finzi, 1913).
The work of Gilbert (1939), Peters (1950), and
Kaplan (1962), led to the general acceptance of
megavoltage extended field radiotherapy for
patients with localised Hodgkin's disease because of
the greatly improved RFS. Relapses occur
following radiotherapy alone, and relapse rates of
20-30% have been associated with mantle radio-
therapy in stage IA-IIB patients (Carmel &
Kaplan, 1976; Peckham et al., 1975; Timothy et al.,
1978). Kaplan defined adverse prognostic factors
for his patients and then advocated radiotherapy
ranging from involved field treatment for
favourable histology (pathologically staged IA
disease in favourable sites), to total nodal
irradiation for PS IB/IIB disease (Kaplan &
Rosenberg, 1975). However, even when extended
field therapy with lung irradiation to patients with
a high risk of relapse was given the overall supra-
diaphragmatic relapse rate was 20% in PS I and II
disease (Carmel & Kaplan, 1976).
Combination chemotherapy developed by DeVita
et al. (1970) improved the cure rate of patients with
advanced stage HD. MOPP or MVPP (Sutcliffe et
al., 1978), are standard treatments for stage IIIB/IV
disease. When chemotherapy is used to salvage
relapsed patients whose localised disease was
treated by radiotherapy alone only about half are
found to have long term survival (Portlock et al.,
1978). For these reasons we initiated a randomised
trial in 1974 to assess the role of adjuvant MVPP in
improving RFS and overall survival in PS IA-IIB
disease. It was also hoped that adverse prognostic
factors at presentation would allow identification of
patients who might benefit from adjuvant chemo-
therapy (ACT).
The trial protocol was written in 1974 when there
were few adjuvant trials in progress. Now several
reports of adjuvant therapy are available for PS
IA-IIB Hodgkin's disease. (Coltman et al., 1979;
Wiernik et al., 1979; Hoppe et al., 1982; Nissen &
Nordentoft, 1982).
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This paper describes the results of a randomised
controlled trial of adjuvant MVPP in 115 patients
after median follow-up of 62 months.
Patients and methods
From October 1974 to August 1981 patients with
newly diagnosed pathologically staged supra-
diaphragmatic Hodgkin's disease (HD) were treated
by mantle radiotherapy and then randomised to
receive ACT with six courses of mustine,
vinblastine, prednisolone and procarbazine (MVPP)
or follow-up. Patients were excluded from the trial
if massive mediastinal disease prevented laparotomy
staging by making the anaesthetic risk too high, or
were outside the age range 16-65 years. One
hundred and fifteen patients were entered into the
trial, but one has been excluded from analysis
because he was lost from follow up.
Patients had routine haematological and
biochemical tests. In addition lymphangiograms
were performed on patients prior to 1976. From
1976 abdominal computerised tomograms were
performed to aid staging. All patients had a routine
staging laparotomy and bone marrow biopsy. The
pathology was reviewed in all cases and classified
according to the Rye classification (Lukes et al.,
1966). Staging was according to the Ann Arbor
classification (Carbone et al., 1971).
Bulk disease was defined as a mass of lymph
nodes outside the chest measuring .5cm in any
one axis. Mediastinal bulk was present if the ratio
of the maximum width of mediastinal disease to the
maximum chest diameter was one third or more.
Patients were examined at first review after radio-
therapy for remission status. A complete remission
was defined as absence of all clinical, biochemical
and radiological evidence of disease. Patients were
then randomised to ACT or follow up alone.
Treatment
The radiotherapy was given by the "mantle"
technique. Anterior and posterior opposed 4Mv
fields were used to encompass the major node areas
in the upper half of the body. The fields extended
from the external auditory meatus superiorly to the
eleventh thoracic vertebra inferiorly, covering the
axillae laterally. The dose delivered at the mid-
plane was 3500cGy in 20 fractions, in 4 weeks.
From the onset of treatment the majority of lung
tissue was shielded by individually fashioned
blocks. The spinal cord was shielded for half the
posterior treatments, and a compensatory anterior
mediastinal lung field was used to deliver 600cGy
on the final treatment day. There was consequently
a dose gradient from 2900cGy in the posterior
mediastinum to 3900cGy in the anterior media-
stinum.
The adjuvant chemotherapy given was 6 courses
of MVPP at 6-weekly intervals, mustine 6mgm-2
(max. 10mg) IV days 1 & 8, vinblastine 6mgm-2
(max 10mg) IV days 1 & 8, prednisolone
40mgday-1 orally days 1-14, and procarbazine
100mgm-2 orally days 1-14.
Patient review
Patients have been reviewed regularly in the clinic.
(After treatment had finished they were reviewed
monthly for the first year, 2-monthly in the second,
3-monthly in the third, four monthly in the fourth,
6-monthly in the fifth, and yearly thereafter). The
median duration of follow up was 62 months
(range 16-97 months).
Statistical methods
The effects of several variables on survival and
RFS have been analysed by calculating Kaplan-
Meier curves, which were then compared using the
logrank test (Peto et al., 1977). Cox's proportional
hazards model (Cox, 1972) had been used to
determine the most significant variables tnat affect
RFS. Both overall survival and RFS have been
calculated from the completion of radiotherapy.
Results
Fifty-five patients were in the radiotherapy (RT)
alone group, and 59 in the ACT group. Patient
characteristics were similar in the two groups
(Table I). All patients attained a complete
Table I Patient characteristics of each treatment group.
RTalone RT+MVPP Total
No. patients 55 59 114
Male 38 39 77
Female 17 20 37
Stage IA 24 23 47
IB 2 2 4
IIA 19 25 44
IIB 10 9 19
Age years (mean) 32.5 31.5
CXR normal 31 35 66
abnormal 24 24 48
Bulk absent 37 34 71
present 18 25 43
Histology LP 16 20 36
NS 22 24 46
MC 17 15 32
LP=Lymphocyte predominant,
sclerosing, MC=Mixed Cellularity.
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remission. This occurred after the start of chemo-
therapy in two patients. Five patients had an extra
radiotherapy field to areas of remaining bulk
disease after mantle treatment, four to the neck and
one to the infraclavicular area. Two of these 5
patients were in the RT group.
Twenty-five of the patients randomised to ACT
received less than 6 courses of MVPP. Seven
received no chemotherapy at all - two patients
refused chemotherapy after randomisation, 3
patients were not given MVPP on medical grounds
(one had severe post RT lethargy and weight loss,
one had hepatitis on liver biopsy, and one had an
isolated C7 nerve palsy investigated until it was too
late to give MVPP), and two had no MVPP for
technical reasons (difficulties with venepuncture).
These 7 patients have been included in the ACT
group for statistical analysis in order to avoid any
bias in the treatment comparisons.
Of the other 18 patients, 8 discontinued chemo-
therapy after developing myelosuppression (two
developed septicaemia), 5 after developing mild
infections, two refused further chemotherapy due to
toxicity, 3 were stopped due to toxicity (one had
severe gastrointestinal colic, one had steroid
induced depression and suicidal tendency, and one
had severe lethargy).
Relapsefree survival (RFS)
The overall 5 year RFS was 81%; 69% in the RT
group and 93% in the ACT group (P=0.002).
(Figure 1). Twenty patients have relapsed, 16/55 in
the RT group (29%) and 4/59 in the ACT group
(7%). In the latter group two who had a CR with
radiotherapy alone, relapsed through ACT and
died, and one did not receive adjuvant treatment
following the finding of hepatitis at laparotomy
liver biopsy (discussed later). The fourth patient
received full ACT. Nine variables were analysed for
effect upon RFS and survival - age, sex, histology,
pathological stage, A/B symptoms, number of sites
involved, CXR status, bulk, and treatment. The
results are shown in Table II. The presence of B
symptoms was the most significant variable
(P=0.0003), adversely affecting RFS. RT alone was
associated with a higher probability of relapse than
RT+ ACT (P=0.002). Bulky disease was
associated with poor RFS (P=0.018), as was an
abnormal CXR (P =0.037), and increasing stage
(P=0.039). The other variables had no statistically
significant effect upon RFS (number of sites
involved, histology, age, and sex). There was no
statistically significant difference in RFS between
those receiving full course ACT and those who
received less chemotherapy than planned.
A Cox's multivariate analysis was performed to
determine those variables with the most significant
100
80
0m
0)
a 60
20
eD 40
20-
Mantle ri
6 MVPP
Mantle
alone
0 20 40 60
Time (months)
Figure 1 Relapse free survival for
with PS IA-IIB Hodgkin's disease.
treatment given.
adiotherapy +
(59)
radiotherapy
(55)
P= 0.002
80 100
all 114 patients
Relationship to
Table II Variables analysed for effect upon survival and
RFS.
P value Logrank test
Variable Survival RFS
Age<36236 0.67 0.45
Sex 0.76 0.79
Histology (LP, NS, MC) 0.30 0.18
Pathological stage 0.05 0.039a
A/B symptoms 0.02a 0.0003a
No. sites involved (1,2,3,4+) 0.22 0.10
CXR normal/abnormal 0.10 0.037a
Bulky disease absent/present 0.002a 0.018a
Treatment group 0.54 0.002a
ap value statistically significant.
effect upon RFS. The results showed that the most
significant variable was treatment group, patients
receiving ACT having fewer relapses. This was
followed in significance by bulk then by B
symptoms, both adversely affecting RFS (Table
III). The other variables were no longer significant.
With these three variables in the model the others
do not add significantly to the ability to predict
RFS. Variables previously significant in the logrank
test (stage and CXR status), were both correlated
with bulk and B symptoms. ACT significantly
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Table III Cox's multivariate analysis of
factors affecting RFS.
P Favourable
value feature
Treatment 0.001 MVPP
Bulk 0.009 Absent
B symptoms 0.029 Absent
100
80
P= 0.008
0 20 40 60
Time (months)
80 100
Figure 2 Relapse free survival for the subgroup of 54
patients with adverse prognostic features at
presentation i.e. bulk disease and/or B symptoms.
Relationship to treatment given.
Table IV Relapse rate according to pathological
stage and treatment given.
RTonly RT+MVPP Overall
Stage (55)8 (59)a (114)8
IA 3/24 1/23 4/47
(12.5%) (4%) (8.5%)
lB 1/2 0/2 1/4
IIA 6/19 1/25 7/44
(32%) (4%) (16%)
IIB 6/10 2/9 8/19
(60%) (22%) (42%)
Total 16/55 4/59 20/114
(29%) (7%) (17.5%)
'No. patients.
Table V Relapse rate associated with the presence or
absence of bulk disease.
RTonly RT+MVPP
no. relapsing/ no. relapsing/
total total
Mediast bulk 3/4 1/5
(75%) (20%)
Mediast bulk+ 2/4 1/5
extrathoracic bulk (50%) (20%)
Extrathoracic bulk 4/10 2/15
only (40%) (13%)
No bulk 7/37 0/34
(19%) (0%)
Total 16/55 4/59
(29%) (7%)
improved RFS in the 54 patients with B symptoms
or bulk disease (Figure 2).
Relapses
Analysis of relapse by stage and treatment group is
shown in Table IV. There were 4 relapses in the
ACT group, and 16 in the RT only group. Overall
4/47 (8.5%) stage IA, 7/44 (16%) stage IIA, 1/4
(25%) stage IB, 8/19 (42%) stage IIB patients
relapsed. Analysing stage IIB alone the relapse rate
was 6/10 (60%) in the RT group, and 2/9 (22%) in
the ACT group.
Twelve of the 20 patients who relapsed had bulk
disease at presentation, 8/16 in the RT group, and
4/4 in the ACT group. Analysis of relapse by bulk
and treatment group is shown in Table V. If bulk
disease was present relapse involving the primary
site occurred in 6/12 cases, whereas none of the
relapses occurring in patients without bulky disease
occurred in the site of initial disease. Mediastinal
bulk was present in 8/55 patients treated by RT
alone, and 10/59 treated with ACT. Relapse
occurred in seven of these 18 patients (39%), 5/8
RT (62%), and 2/10 ACT (20%).
An analysis of the site of relapse in relation to
radiotherapy field showed nine relapses outside the
field, six within, and five relapses occurred
simultaneously inside and outside the radiotherapy
field. Ten relapses occurred in nodes alone, and 6
in extranodal sites alone (one in bone, 2 in liver
and bone, one in the lung, liver, diaphragm, and
pericardium, one in the pleura and chest wall, and
one in the humerus and overlying skin). Four
patients had simultaneous nodal and extranodal
relapse (3 mediastinum and lung, and one in para-
aortic glands and bone).
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Salvage treatment
Of the 4 patients relapsing in the ACT group, 2
relapsed during ACT and died of HD (both had PS
IIB disease with mediastinal bulk at presentation).
One patient with pulmonary and hilar relapse failed
to respond to MVPP or radiotherapy and died of
disease. The fourth patient received no ACT
(hepatitis on liver biopsy), and achieved a CR on
MVPP.
Sixteen relapsed after RT alone, and 13 achieved
a CR on chemotherapy (11 MVPP and 2
Chlorambucil VPP). Seven of these patients
received adjuvant radiotherapy to sites of relapse.
One patient received no treatment because the
relapse was diagnosed at post mortem. Another
patient failed to achieve a CR after relapse in the
skin and bone and died of HD, septicaemia and
disseminated herpes zoster. The remaining patient
achieved a CR using MVPP after mediastinal and
pleural relapse. He then had a second relapse and
died of disseminated herpes zoster and HD.
Table II. Survival was adversely affected by the
presence of bulk disease (P=0.002), and B
symptoms (P=0.02). Pathological stage was of
borderline significance (P=0.05)- stage II patients
doing less well than stage I. The other variables
were of no prognostic significance. A multivariate
analysis of these variables was not possible, owing
to the small number of deaths involved. Figure 4
shows no significant survival advantage to patients
receiving ACT when bulk and/or B symptoms were
present.
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Survival
The overall 5 year survival rate was 93%. There
was no statistically significant difference between
the two treatment groups (94% for RT alone and
91% for ACT P=0.54- Figure 3). The logrank
test was used to determine the effect of nine
variables on survival. The results are shown in
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Figure 4 Overall survival for the subgroup of 54
patients with adverse prognostic features at
presentation i.e. bulk disease and/or B symptoms.
Relationship to treatment given.
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Figure 3 Overall survival for all 114 p-
IA-IIB Hodgkin's disease. Relationshil
given.
There were 8 deaths, 3 in the radiotherapy alone
group and 5 in the ACT group. (PS IA (1), IIA (3),
IIB (4)). They all had bulky disease at presentation.
Two patients died from intercurrent causes - one
following dental extraction, and the other from a
secondary carcinoma of unknown primary site. The
first patient died in complete remission, two months
after finishing MVPP chemotherapy for relapsed
8'0 100 HD. He was in the ACT group (but received no
chemotherapy because the laparotomy liver biopsy
showed changes of hepatitis.) He died of
atients with PS pneumococcal septicaemia 5 days after dental
p to treatment treatment. The other patient had only one course of
adjuvant treatment because she developedsl
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septicaemia when leucopenic. Her second
malignancy became apparent 4 months after
attaining a complete remission from Hodgkin's
disease.
Of the remaining 6 patients dying with active
disease, 3 were in each treatment group. Two
receiving ACT relapsed through chemotherapy. The
other relapsed with mediastinal and lung disease
and died of pneumonia and progressing HD. Of the
three dying after radiotherapy alone, in one patient
HD was identified in the paratracheal glands at
postmortem examination following death from
E.coli septicaemia. There had been no clinical
evidence of relapse. Of the other two, one died in
his first, and the other in his second relapse.
Discussion
This trial of adjuvant chemotherapy following
radiotherapy for localised Hodgkin's disease was
different from other randomised trials in two
respects - the radiotherapy was the same in both
arms of the trial (mantle RT), and MVPP was used
rather than MOPP. It has been shown that
remission rates and survival in advanced Hodgkin's
disease are similar for MOPP and MVPP therapy,
however MVPP has less neurotoxicity (Nicholson et
al., 1970; Sutcliffe et al., 1978; Crowther, 1979;
DeVita et al., 1980).
We have shown that 5 year RFS for PS IA-IIB
HD patients has been significantly improved by
adjuvant MVPP, although there was no
improvement in overall survival. Four other
randomised studies of adjuvant chemotherapy in
patients with localised pathologically staged HD
have been published. They are summarised in Table
VI. Stanford compared radiotherapy alone using
varied fields (involved field, mantle, +lung or sub-
diaphragmatic irradiation depending on the patient
prognostic factors), with involved or extended field
radiotherapy followed by 6 courses of MOPP
(Rosenberg & Kaplan, 1975; Rosenberg et al., 1979;
Hoppe et al., 1982). In their study, ACT
significantly improved RFS in PS IA/IIA disease
but not in IB/IIB disease. This contrasts with our
study which showed benefit for patients with B
symptoms following ACT. The probable reason for
this difference may be the more extensive radio-
therapy fields given at Stanford to patients with B
symptoms in the RT alone arm. Stanford showed
borderline survival advantage at 10 years follow-up
after ACT to patients with IA/IIA disease but the
overall survival of Stanford patients with
mediastinal bulk at presentation was the same in
both arms of the trial.
The Southwest Oncology Group (SWOG) has
also shown an improved RFS after ACT. The
compared involved field RT plus adjuvant MOPP
with extended field RT alone, and they found
mediastinal disease, E disease and B symptoms to
be adverse prognostic factors associated with
increased RFS when given ACT. They also failed
to show an overall survival advantage from ACT
(Coltman et al., 1979).
A study from Denmark compared TNI with
mantle RT followed by six courses of MOPP. This
again showed RFS benefit from ACT but no
overall survival advantage (Nissen & Nordentoft,
1982).
Wiernik et al. (1979) randomised 87 PS IA,
IIA/B and IIIA patients to receive extended field
radiotherapy followed by adjuvant MOPP or follow
up. Their median follow up is 69 months. For 46
Table VI Summary of randomised trials of adjuvant combination chemotherapy in PSIA-IIB
Hodgkin's disease.
Adjuvant chemotherapy
significantly improves
Authors No. Years Treatment RFS Survival
Coltman 206 1972-1978 EF Yes No
et al., 1979 IF+6MOPP
Hoppe 230 1968-1978 EF/STLI/TLI Yes-only No
et al., 1982 IF/STNI/TNI+6MOPP med.bulk
Nissen 261 1971-1980 TNI Yes No
et al., 1982 Mantle+6MOPP
Wiernik 46 1970-1974 EF Yes No
et al., 1979 EF+6MOPP
IF=Involved field radiotherapy.
EF=Extended field radiotherapy.
STNI=subtotal nodal irradiation.
TNI=total nodal irradiation.RANDOMISED STUDY OF ADJUVANT MVPP IN PS IA-IIB HD 701
PS I/II patients the relapse rate is 31% with RT
alone and 6% with ACT. No patients died in the
ACT arm, but the difference was not statistically
significant.
Salvage was successful in 13/16 (81%) of our
relapsing patients in the RT only group. Follow up
is short at present. Others report similar results
(Nissen et al., 1980; Timothy et al., 1979; Wiernik
et al., 1979). Less favourable rates have been
reported following RT alone in PS IA-IIB patients
(Portlock et al., 1978). Salvage results depend upon
the site of relapse and extent of disease.
The number of courses of ACT is controversial,
and studies in clinically staged patients with three
courses of MOPP following radiotherapy show
improved RFS (Andrieu et al., 1980; Teillet et al.,
1981).
Against the efficacy of chemotherapy one must
weigh the toxicity, especially the development of
sterility and second malignancies (Nissen et al.,
1980; Wiernik et al, 1979; Andrieu et al., 1980;
Crowther, 1980). The combination of adriamycin,
bleomycin, vinblastine and DTIC (ABVD) seems to
be as effective as MOPP, but causes less sterility
and second malignancies (Santoro et al., 1983).
However, in combination with radiotherapy ABVD
may be associated with an increased risk of
pulmonary fibrosis. Adjuvant chemotherapy may
cause myelotoxicity. Severe neutropenia (neutro-
phils < 1.0 x 1091-1) occurred in three of our
patients. Two developed septicaemia. These three
and five others with asymptomatic thrombocy-
topenia discontinued the adjuvant chemotherapy.
Since overall survival is not improved most
patients with localised HD can be safely and
effectively treated with radiotherapy alone. Adverse
prognostic factors should be taken into account so
that therapy can be chosen for each patient
ensuring maximum chance of cure with minimal
short and long term treatment associated
complications. This approach has recently been
critically reviewed (Crowther, 1984). Our results
and those of other groups show a high relapse rate
in patients with B symptoms (Aisenberg, 1978;
Mintz et al., 1979; Coltman et al., 1979), and bulky
mediastinal disease (Lee et al., 1980; Mauch et al.,
1978) treated by RT alone. Combined modality
treatment of mediastinal bulk with large volumes of
lung and heart irradiation may be associated with
morbidity due to pericarditis and pneumonitis. The
role of prophylactic lung irradiation for patients
with mediastinal bulk needs further assessment to
determine efficacy and long term complications
(Lee et al., 1981; Torti et al., 1981). A case can be
made that patients with B symptoms should have
initial chemotherapy, avoiding the use of radio-
therapy unless bulk is present. Increased RFS
would be expected, however survival advantage
remains to be proven. Longer follow up of large
groups of patients will answer this question.
The majority of patients with PS IA-IIB
Hodgkin's disease do not require chemotherapy.
Although ACT improved RFS it did not improve
survival. Many patients did not receive full
adjuvant treatment because of toxicity. Patients
who benefited, with improved relapse free survival
were those with mediastinal bulk and B symptoms.
Theses patients may need combined modality
treatment or more aggressive radiotherapy. The
best chemotherapy regimen and number of courses
required need to be determined. The aims of the
oncologist are to improve the cure rate of HD
patients presenting with adverse prognostic features
and to reduce treatment related toxicity.
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